藥師幫(09885.HK)前4個月自有品牌業務交易總額5.6億元 同比增長532.3%
格隆匯5月14日丨藥師幫(09885.HK)公告,廠牌首推業務乃集團「向上走」方案中的一項重要戰略,同時作爲高利潤業務,因此對提升盈利能力而言舉足輕重。誠如年報所披露,根據公司自其他業務運營所獲得的洞察,公司積極尋求與藥企建立深度合作,旨在協助它們將針對下遊需求定製的產品推向更廣闊的市場,從而將潛在的市場機遇轉化爲實實在在的銷售業績。另一方面,依託公司已經構建的品牌影響力和渠道優勢,其戰略性推進自有品牌產品的拓展,致力於推出品類豐富且緊密貼合市場需求的高質量自有品牌產品,以滿足更廣泛下遊用戶的多元化需求。
截至2025年4月30日止4個月,廠牌首推業務(包括集團自有品牌業務)交易總額7.17億元人民幣,同比增長108.1%;集團自有品牌業務交易總額5.6億元,同比增長532.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.